Physicians Financial Services Inc. Has $690,000 Stock Position in The Clorox Company (NYSE:CLX)

Physicians Financial Services Inc. lowered its stake in The Clorox Company (NYSE:CLX) by 9.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 4,685 shares of the company’s stock after selling 470 shares during the period. Physicians Financial Services Inc.’s holdings in Clorox were worth $690,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of CLX. American Century Companies Inc. grew its position in shares of Clorox by 17.9% during the 4th quarter. American Century Companies Inc. now owns 76,400 shares of the company’s stock worth $12,408,000 after purchasing an additional 11,606 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Clorox by 5.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 229,291 shares of the company’s stock worth $37,349,000 after purchasing an additional 11,953 shares in the last quarter. Elo Mutual Pension Insurance Co grew its position in shares of Clorox by 21.4% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 13,396 shares of the company’s stock worth $2,176,000 after purchasing an additional 2,365 shares in the last quarter. NEOS Investment Management LLC grew its position in shares of Clorox by 27.7% during the 4th quarter. NEOS Investment Management LLC now owns 5,715 shares of the company’s stock worth $928,000 after purchasing an additional 1,241 shares in the last quarter. Finally, Blair William & Co. IL grew its position in shares of Clorox by 1.2% during the 4th quarter. Blair William & Co. IL now owns 9,271 shares of the company’s stock worth $1,506,000 after purchasing an additional 107 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Trading Down 0.5%

NYSE:CLX opened at $130.80 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.44 and a debt-to-equity ratio of 13.07. The stock has a market capitalization of $16.12 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 3.44 and a beta of 0.51. The firm has a fifty day simple moving average of $126.77 and a two-hundred day simple moving average of $140.00. The Clorox Company has a 12 month low of $117.35 and a 12 month high of $171.37.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The firm’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 earnings per share. Analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Activity

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director directly owned 4,000 shares of the company’s stock, valued at $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.57% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CLX shares. Wells Fargo & Company dropped their price target on shares of Clorox from $142.00 to $135.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 9th. Citigroup reaffirmed a “neutral” rating and set a $135.00 price target (down previously from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Barclays set a $119.00 price objective on shares of Clorox and gave the stock an “underweight” rating in a research report on Tuesday, July 15th. Finally, Evercore ISI set a $140.00 price objective on shares of Clorox and gave the stock an “underperform” rating in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $144.83.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.